Solabegron

CAS : 252920-94-8

Ref. 3D-CKA92094

Informations sur le produit

• Nom: Solabegron
• Synonymes: (-)-(R)-3′-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]biphenyl-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino][1,1′-biphenyl]-3-carboxylic acid, Gw 427353, [1,1′-Biphenyl]-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-

Description

Solabegron is a drug that has clinical relevance for the treatment of bladder disorders. It is an agonist of the beta-3 adrenergic receptor, with no affinity for beta-1 or beta-2 receptors. In animal models, solabegron has been shown to increase detrusor muscle contractility and reduce urinary symptoms. Solabegron also acts as an inhibitor of DPP-IV, which is involved in the breakdown of glucagon-like peptide (GLP). The drug reduces body mass index and improves metabolic disorders in animals by stimulating GLP secretion. Solabegron is metabolized by CYP3A4 and has hydrogen bonding interactions with drugs such as erythromycin, clarithromycin, and telithromycin.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 410.89 g/mol
• Formule: C₂₃H₂₃ClN₂O₃
• Degré de pureté: Min. 95%